<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02884479</url>
  </required_header>
  <id_info>
    <org_study_id>SCI-PT112-ONC-P1-001</org_study_id>
    <nct_id>NCT02884479</nct_id>
  </id_info>
  <brief_title>An Open-Label Phase I/II Clinical Study of PT-112 in Combination With Docetaxel in Subjects With Advanced Solid Tumor in a Phase I Dose Escalation Study and in Subjects With Non-Small Cell Lung Cancer (NSCLC) in a Phase II Dose Confirmation Study</brief_title>
  <official_title>An Open-Label Phase I/II Clinical Study of PT-112 in Combination With Docetaxel in Subjects With Advanced Solid Tumor in a Phase I Dose Escalation Study and in Subjects With Non-Small Cell Lung Cancer (NSCLC) in a Phase II Dose Confirmation Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SciClone Pharmaceuticals International (Cayman) Development Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Parexel</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cheng-Kung University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>SciClone Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test PT-112 in Combination with Docetaxel in Subjects with&#xD;
      Advanced Solid Tumor in a Phase I Dose Escalation Study and in Subjects with Non-Small Cell&#xD;
      Lung Cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>August 2016</start_date>
  <completion_date type="Anticipated">March 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>dose-limiting toxicities (DLTs)</measure>
    <time_frame>Day 0 to Day 28</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>area under the plasma concentration-time curve from 0 to the last measurable concentration (AUClast)</measure>
    <time_frame>Cycle 1, Day 1: Pre-dose, 0.5, 1, 1.25, 1.5, 2, 3, 5, 8, 12, 24 hours post dose Cycle 1, Day 8: Pre-dose, 0.5, 1, 1.5, 2, 3, 5, 8, 12, 24 hours post dose Cycle 2, Day 8: Pre-dose, 1, 2, 4 hours post dose Cycle 3 &amp; 4, Day 8: Pre-dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>Cycle 1: Day 1, Day 8, Day 15; Cycle 2: Day 1, Day 8; Follow up: 30 days post final dose</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Advanced Solid Tumor</condition>
  <condition>Non-Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>PT-112 + Docetaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Increasing doses of intravenously administered PT-112 in combination with 60 mg/m2 docetaxel every 3 weeks (Q3W) in subjects with advanced solid tumor of any histological type.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PT-112</intervention_name>
    <description>Increasing doses of intravenously administered PT-112 in combination with 60 mg/m2 docetaxel every 3 weeks (Q3W) in subjects with advanced solid tumor of any histological type.</description>
    <arm_group_label>PT-112 + Docetaxel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>Increasing doses of intravenously administered PT-112 in combination with 60 mg/m2 docetaxel every 3 weeks (Q3W) in subjects with advanced solid tumor of any histological type.</description>
    <arm_group_label>PT-112 + Docetaxel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        - Subjects must meet all of the following inclusion criteria to be eligible for enrollment&#xD;
        into the study:&#xD;
&#xD;
          1. Male or female ≥ 20 years of age on the day of signing informed consent.&#xD;
&#xD;
          2. Subjects with advanced tumor of any histological type and meet the following&#xD;
             eligibility criteria for the corresponding part of the study:&#xD;
&#xD;
               -  In Part 1, the subjects who failed at least one prior therapy must have&#xD;
                  pathologically confirmed advanced solid tumor of any histological type with&#xD;
                  preference of subjects with advanced NSCLC and either no available, or&#xD;
                  intolerable to, standard of-care treatment.&#xD;
&#xD;
               -  In Part 2, the subjects must have pathologically confirmed advanced NSCLC.&#xD;
                  Subjects are required to have evidence of measurable disease per RECIST v1.1.&#xD;
&#xD;
          3. Eastern Collaborative Oncology Group (ECOG) Performance Status ≤ 1.&#xD;
&#xD;
          4. Subject must have adequate organ function as indicated by the following laboratory&#xD;
             values:&#xD;
&#xD;
               -  Absolute neutrophil count (ANC) ≥ 1.5 × 109/L.&#xD;
&#xD;
               -  Platelets ≥ 100 × 109/L.&#xD;
&#xD;
               -  Hemoglobin ≥ 90 g/L or 5.6 mmol/L.&#xD;
&#xD;
               -  Serum creatinine ≤ 1.5 × upper limit of normal (ULN), or calculated or directly&#xD;
                  measured creatinine clearance ≥ 60% lower limit of normal (LLN).&#xD;
&#xD;
               -  Serum total bilirubin ≤ 1.5 × ULN (subjects with Gilbert's Syndrome are allowed&#xD;
                  if direct bilirubin is within normal limits).&#xD;
&#xD;
               -  Aspartate aminotransferase (AST [SGOT]) and/or alanine aminotransferase (ALT&#xD;
                  [SGPT]) ≤ 2.5 × ULN, or ≤ 5 × ULN in presence of liver metastases.&#xD;
&#xD;
               -  International normalized ratio (INR) or prothrombin time (PT) ≤ 1.5 × ULN.&#xD;
&#xD;
               -  Activated partial thromboplastin time (aPTT) ≤ 1.5 × ULN.&#xD;
&#xD;
               -  Albumin ≥ 3 mg/dL.&#xD;
&#xD;
          5. Female subjects are eligible to enter and participate in the study if they are of:&#xD;
&#xD;
               -  Non-childbearing potential (i.e., physiologically incapable of becoming&#xD;
                  pregnant), including any female who&#xD;
&#xD;
               -  has had a hysterectomy&#xD;
&#xD;
               -  has had a bilateral oophorectomy (ovariectomy)&#xD;
&#xD;
               -  has had a bilateral tubal ligation&#xD;
&#xD;
               -  is post-menopausal (total cessation of menses for ≥ 1 year)&#xD;
&#xD;
               -  Childbearing potential, have a negative serum pregnancy test at screening (within&#xD;
                  7 days of the first investigational product administration), are not breast&#xD;
                  feeding, and use adequate contraception before study entry and throughout the&#xD;
                  study until 180 days after the last investigational product administration.&#xD;
                  Adequate contraception, when used consistently and in accordance with both the&#xD;
                  product label and the instructions of the physician, are defined as follows:&#xD;
&#xD;
               -  Vasectomized partner who is sterile prior to the female subject's entry and is&#xD;
                  the sole sexual partner for that female.&#xD;
&#xD;
               -  Any intra-uterine device with a documented failure rate of less than 1% per year.&#xD;
&#xD;
               -  Double barrier contraception defined as condom with spermicidal jelly, foam,&#xD;
                  suppository, or film; or diaphragm with spermicide; or male condom and diaphragm.&#xD;
&#xD;
          6. Male subjects are eligible to enter and participate in the study if they are&#xD;
             vasectomized or agree to use of contraception during the study treatment period and&#xD;
             for at least 180 days after the last dose of the study drug.&#xD;
&#xD;
          7. Willing and able to provide written informed consent and comply with the requirements&#xD;
             of the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects meeting any of the following criteria are ineligible for participation in the&#xD;
             study:&#xD;
&#xD;
               1. Any cytotoxic chemotherapy within 21 days, prior to initiation of study drug.&#xD;
&#xD;
               2. Receipt of more than three prior regimens of cytotoxic chemotherapy&#xD;
                  (immunotherapy and targeted therapy will not be counted as a line of therapy).&#xD;
&#xD;
               3. History of hypersensitivity reaction to docetaxel and polysorbate 80 or any of&#xD;
                  its components.&#xD;
&#xD;
               4. Presence of an acute or chronic toxicity of prior chemotherapy, with the&#xD;
                  exception of alopecia, that has not resolved to Grade 1, as determined by&#xD;
                  National Cancer Institute's Common Terminology Criteria for Adverse Events&#xD;
                  (NCI-CTCAE) Version 4.03.&#xD;
&#xD;
               5. Evidence of peripheral neuropathy of Grade 2 or greater within 28 days prior to&#xD;
                  initiation of dosing.&#xD;
&#xD;
               6. Symptomatic brain metastasis requiring active treatment.&#xD;
&#xD;
               7. Bone marrow reserve which, in the clinical judgment of the Principal&#xD;
                  Investigator, is not adequate for participation in this study.&#xD;
&#xD;
               8. Known allergy or hypersensitivity to Pt-containing agents, or known intolerance&#xD;
                  to a prior Pt-containing agent which, in the judgment of the Principal&#xD;
                  Investigator, precludes re-exposure to a Pt-containing agent.&#xD;
&#xD;
               9. Radiotherapy within 28 days prior to baseline and/or receipt of radiotherapy to&#xD;
                  &gt;25 % of bone marrow volume.&#xD;
&#xD;
              10. Major surgery within 28 days prior to initiation of study drug combination.&#xD;
&#xD;
              11. Life expectancy &lt;12 weeks.&#xD;
&#xD;
              12. Active or clinically unstable bacterial, viral, or fungal infection requiring&#xD;
                  systemic therapy.&#xD;
&#xD;
              13. Known human immunodeficiency virus or acquired immunodeficiency syndrome-related&#xD;
                  illness.&#xD;
&#xD;
              14. Clinically significant hearing impairment, as judged by the Principal&#xD;
                  Investigator.&#xD;
&#xD;
              15. Any of the following within 3 months prior to initiation of study drug:&#xD;
                  uncontrolled congestive heart failure (New York Heart Association Classification&#xD;
                  3 or 4, APPENDIX 2), angina, myocardial infarction, cerebrovascular accident,&#xD;
                  coronary/peripheral artery bypass graft surgery, transient ischemic attack, or&#xD;
                  pulmonary embolism.&#xD;
&#xD;
              16. Unstable cardiac dysrhythmias or persistent prolongation of the QTc (Fridericia)&#xD;
                  interval to &gt;450 msec for males or &gt;470 msec for females.&#xD;
&#xD;
              17. In Part 2, any previous malignancy, except for non squamous-cell carcinoma of&#xD;
                  skin or carcinoma-in-situ of the uterine cervix, unless the tumor was&#xD;
                  successfully treated with curative intent more than two years prior to study&#xD;
                  entry.&#xD;
&#xD;
              18. Use of any investigational agents within 28 days prior to the screening.&#xD;
&#xD;
              19. Pregnant or lactating female.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wu-Chou Su</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cheng-Kung University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Crystal Qin, M.D, Ph.D</last_name>
    <phone>86-21-2319 3802</phone>
    <email>cqin@sciclone.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Changhua Christian Hospital</name>
      <address>
        <city>Changhua County</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chien-Te Li</last_name>
    </contact>
    <investigator>
      <last_name>Chien-Te Li</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>China Medical University &amp; Hospital</name>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Te-Chun Hsia</last_name>
    </contact>
    <investigator>
      <last_name>Te-Chun Hsia</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Cheng Kung University Hospital</name>
      <address>
        <city>Tainan City</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wu-Chou Su</last_name>
    </contact>
    <investigator>
      <last_name>Wu-Chou Su</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tri-Service General Hospital</name>
      <address>
        <city>Taipei City</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ching-Lian Ho</last_name>
    </contact>
    <investigator>
      <last_name>Ching-Lian Ho</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <study_first_submitted>August 17, 2016</study_first_submitted>
  <study_first_submitted_qc>August 30, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2016</study_first_posted>
  <last_update_submitted>April 23, 2018</last_update_submitted>
  <last_update_submitted_qc>April 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

